Citation Impact
Citing Papers
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
2020 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
2023 Standout
Platelet function in HIV plus dengue coinfection associates with reduced inflammation and milder dengue illness
2019
Barriers to healthcare for transgender individuals
2016 Standout
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
2009
PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events
2007
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
2013
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients
2007
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients
2008
Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond
2018
Fixed-Dose Ibuprofen/Famotidine: A Review of Its Use to Reduce the Risk of Gastric and Duodenal Ulcers in Patients Requiring NSAID Therapy
2013
Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir
2008
Current role of LC-MS in therapeutic drug monitoring
2007
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Clinical management of tuberculosis and HIV-1 co-infection
2010
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Albumin–drug interaction and its clinical implication
2013 Standout
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
2011 Standout
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
2020
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks
2012
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
2010
Genetics of HIV-associated sensory neuropathy and related pain in Africans
2017
COVID-19: A promising cure for the global panic
2020 Standout
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy
2015
HLA-B*5701 Screening for Hypersensitivity to Abacavir
2008 Standout
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir
2009
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
2011
Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy
2008
Exosomes: biogenesis, biologic function and clinical potential
2019 Standout
Coarse-Grained Model of Proteins Incorporating Atomistic Detail of the Active Site
2005
Health and Health Care Among Male-to-Female Transgender Persons Who Are HIV Positive
2005
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents
2010
Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review
2018 Standout
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
2009
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
2005
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
2006
Use of therapeutic drug monitoring in HIV disease
2008
HIV-induced alteration in gut microbiota
2014
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients
2006
The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain
2015 Standout
Exosomes in human semen restrict HIV-1 transmission by vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex
2015
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
2009
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
2009
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
<p>Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics</p>
2019 Standout
Tests for Latent Tuberculosis in People With ESRD: A Systematic Review
2012
A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase
2018 StandoutNobel
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
2009
Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions
2005
Depo-medroxyprogesterone in Women on Antiretroviral Therapy: Effective Contraception and Lack of Clinically Significant Interactions
2006
Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors
2012
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring
2014 StandoutNobel
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
2009
Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients
2007
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
2009
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity
2010
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
2015 Standout
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
2006
Chronic Kidney Disease
2016 Standout
Advancements in nano-enabled therapeutics for neuroHIV management
2016
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
2020 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis
2008 Standout
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir
2008
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
The MARTINI Coarse-Grained Force Field: Extension to Proteins
2008 Standout
Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug design
2020
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
2021
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Diabetic Cardiomyopathy
2018 Standout
Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV‐Infected Patients with Chronic Hepatitis C
2007
Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
2010
Neuropathic Pain: From Mechanisms to Treatment
2020 Standout
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option
2020
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation
2016 StandoutNobel
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
2016 Standout
Transcription Factor CREM Mediates High Glucose Response in Cardiomyocytes and in a Male Mouse Model of Prolonged Hyperglycemia
2017
Interventions for enhancing medication adherence
2014 Standout
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
The Immune Response in Tuberculosis
2013 Standout
Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone
2009
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors
2011
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Update on rifampin, rifabutin, and rifapentine drug interactions
2012
VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
2006
Rational Design of Doravirine: From Bench to Patients
2019
Pharmacogenetics of Anti-HIV Drugs
2007
Works of Marta Boffito being referenced
Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses
2006
Protein Binding in Antiretroviral Therapies
2003
The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests
2004
Effects of the H 2 -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients
2011
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
2006
Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
2008
Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
2014
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
2004
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs
2008
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
2007
Stopping antiretroviral therapy
2007
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects
2002
Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals
2013
Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1
2009
Long-acting antiviral agents for HIV treatment
2015
The management of HIV-1 protease inhibitor pharmacokinetic interactions
2005
Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression
2008
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
2005
Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine
2008
Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients
2004
Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval
2004
Clinical use of lopinavir/ritonavir in a salvage therapy setting
2002
Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies
2006
Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients
2008
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
2014
The pharmacokinetics of HIV protease inhibitor combinations
2005
Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings
2016
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV‐positive subjects
2008
Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
2015
Pharmacokinetic implications of resistance
2006
Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects
2010
Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients
2004
Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation
2008
Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents
2009
The Clinical Implications of Antiretroviral Pharmacogenomics
2006
Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy
2005
Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs
2005
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk
2019
Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients
2007
Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting
2005
Lopinavir Measurement in Pleural Effusion in a Human Immunodeficiency Virus Type 1-Infected Patient with Kaposi's Sarcoma
2002
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials
2009
Antiretroviral therapy to reduce the sexual transmission of HIV.
2003